India-bred private equity firm Chrys Capital is set to buy 10 per cent in fast-growing Mankind Pharmaceuticals for $350 million. GIC of Singapore and CPPIB of Canada may co-invest in the deal, likely to be signed this week.
Desai & Diwanji advised
Update 29 May 2019: Platinum Partners advised
Shardul Amarchand Mangaldas and Khaitan & Co also advised.
2018-04-06
Deal value: Approx USD 350 mn
This deal report is based on a firm's press release and may be only partially complete. Some firms or names of advisers may be therefore be missing.
No comments yet: share your views